Hepatic Steatosis Index Calculator- Free NAFLD MASLD Fatty Liver Screening Tool

About This Hepatic Steatosis Index (HSI) Calculator

This free Hepatic Steatosis Index calculator is designed for healthcare professionals, researchers, and individuals seeking a validated non-invasive screening tool for fatty liver disease. The calculator computes your HSI score using the formula developed by Lee et al. in their landmark 2010 study of 10,724 subjects, helping to identify candidates for liver ultrasonography and lifestyle modifications for NAFLD and MASLD.

The HSI calculation uses your alanine aminotransferase (ALT) and aspartate aminotransferase (AST) liver enzyme values from routine blood tests, combined with your body mass index (BMI), biological sex, and type 2 diabetes status. The formula follows the validated equation: HSI = 8 x (ALT/AST) + BMI + 2 (if female) + 2 (if diabetic). This methodology is endorsed by the European Association for the Study of the Liver (EASL) for large-scale screening studies and has been validated across diverse global populations.

The calculator displays your HSI score on an intuitive reference range bar showing three validated clinical zones: below 30 (NAFLD ruled out with 93.1% sensitivity), 30 to 36 (indeterminate), and 36 or above (NAFLD likely with 92.4% specificity). The component breakdown analysis shows the relative contribution of each formula variable to your total score, helping you understand which factors most influence your result. Additional tabs provide detailed formula calculations, BMI classification according to WHO standards, and a comparison of available non-invasive steatosis screening tools.

Hepatic Steatosis Index (HSI) Calculator: Complete Guide to Non-Invasive Fatty Liver Screening

The Hepatic Steatosis Index (HSI) is a validated, non-invasive screening tool designed to identify individuals likely to have non-alcoholic fatty liver disease (NAFLD), now increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). Developed by Lee et al. in 2010 through a cross-sectional study of 10,724 health check-up subjects, the HSI uses readily available clinical and laboratory parameters to estimate the probability of hepatic steatosis without requiring imaging or liver biopsy. With MASLD now affecting approximately 30% of the global adult population and projected to exceed 55% by 2040, simple screening tools like the HSI have become essential for early detection and clinical risk stratification.

Unlike invasive procedures such as liver biopsy or expensive imaging modalities like magnetic resonance imaging proton density fat fraction (MRI-PDFF) and controlled attenuation parameter (CAP), the HSI relies solely on routine blood test results and basic anthropometric measurements. This makes it an economical, practical, and widely accessible tool for primary care settings, population-based screening programs, and epidemiological research worldwide. The HSI has been validated across multiple diverse populations and is endorsed by the European Association for the Study of the Liver (EASL) as a screening tool suitable for large-scale studies.

Understanding Non-Alcoholic Fatty Liver Disease and MASLD

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions characterized by excessive fat accumulation in hepatocytes (liver cells) in individuals who consume little to no alcohol. The disease ranges from simple steatosis, where fat deposits in the liver without significant inflammation, to non-alcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis (MASH), which involves inflammation and can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. In 2023, an international expert consensus updated the nomenclature from NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting the metabolic underpinnings of the condition.

The global prevalence of NAFLD/MASLD has reached approximately 30% of all adults, with rates varying significantly by region. Latin America reports the highest prevalence at around 44%, followed by the Middle East and North Africa at approximately 37%, South Asia at 34%, and Europe and North America each near 30%. Among individuals with type 2 diabetes, the prevalence is dramatically higher, with pooled global estimates reaching approximately 65%. MASLD is now recognized as the hepatic component of metabolic syndrome and has become a leading indication for liver transplantation globally. By 2040, adult MASLD prevalence is projected to exceed 55%, making early screening and detection more important than ever.

The HSI Formula: Variables and Their Clinical Significance

The Hepatic Steatosis Index incorporates four variables, each with distinct clinical relevance to fatty liver disease. Understanding these components helps healthcare providers and patients interpret the results meaningfully.

The ALT/AST ratio is the most heavily weighted component, multiplied by a factor of 8 in the formula. Alanine aminotransferase (ALT) is an enzyme found predominantly in the liver, making it relatively specific for hepatocellular injury. Normal ALT ranges are typically 7 to 56 U/L, though many experts now suggest lower thresholds of around 30 U/L for males and 19 to 25 U/L for females to improve sensitivity for detecting subclinical liver disease. Aspartate aminotransferase (AST) is found in the liver but also in the heart, skeletal muscle, kidneys, and brain. Normal AST ranges are typically 10 to 40 U/L. In NAFLD, ALT tends to be elevated proportionally more than AST, resulting in an ALT/AST ratio greater than 1. This pattern reverses in alcoholic liver disease and advanced cirrhosis, where AST predominates.

Body mass index (BMI) directly contributes to the HSI score and reflects the strong association between obesity and fatty liver disease. Higher BMI values increase the HSI score proportionally. The diabetes mellitus modifier adds 2 points to the HSI, reflecting the well-established bidirectional relationship between type 2 diabetes and MASLD, where approximately 65% of individuals with type 2 diabetes have concurrent fatty liver disease. The female sex modifier also adds 2 points, accounting for sex-based differences in liver enzyme distribution and metabolic risk profiles.

Clinical Interpretation of HSI Results

The Hepatic Steatosis Index provides a continuous numerical score that is interpreted using two validated thresholds. These cutoff values were established in the original derivation and validation cohorts by Lee et al. and have been confirmed in subsequent studies across multiple populations.

An HSI value below 30 rules out NAFLD with a sensitivity of 93.1% and a negative likelihood ratio of up to 0.186. This means that fewer than 7 out of 100 individuals with an HSI below 30 who actually have NAFLD would be missed by this screening threshold. The negative predictive value was reported at 84.3% (95% confidence interval: 82.1% to 86.2%). Individuals scoring below this threshold can generally be reassured, though clinical judgment should always consider the full clinical picture.

An HSI value of 36 or above detects NAFLD with a specificity of 92.4% and a positive likelihood ratio starting from 6.069. The positive predictive value was 85.9% (95% confidence interval: 83.9% to 87.6%). Individuals with an HSI at or above 36 should be considered candidates for liver ultrasonography and further metabolic evaluation. In the original study, of 2,692 subjects with HSI below 30 or above 36, 2,305 (85.6%) were correctly classified.

An HSI value between 30 and 36 falls in an indeterminate zone. Individuals in this range may or may not have hepatic steatosis, and further evaluation with imaging or additional non-invasive markers should be considered based on overall metabolic risk profile, family history, and other clinical factors.

Diagnostic Performance and Validation Studies

The HSI was originally developed and validated in a Korean population of 10,724 health check-up subjects, of whom 5,362 were diagnosed with NAFLD by ultrasonography. The derivation cohort demonstrated an area under the receiver operating characteristic curve (AUROC) of 0.812 (95% confidence interval: 0.801 to 0.824), indicating good discriminatory ability. The index was subsequently validated in an independent cohort from the same institution.

Since its development, the HSI has been evaluated in numerous populations across diverse ethnic and clinical settings. Studies in patients with type 2 diabetes have demonstrated particularly strong performance, with one study reporting an AUROC of 0.979 (95% CI: 0.962 to 0.997), sensitivity of 89.55%, specificity of 95.24%, a positive predictive value of 94.49%, and a negative predictive value of 90.91%. The HSI has also been validated in patients with obstructive sleep apnea, chronic hepatitis B, and various metabolic conditions.

Comparative studies have evaluated the HSI alongside other non-invasive steatosis indices. When compared to the Fatty Liver Index (FLI), which requires triglyceride levels, gamma-glutamyl transferase (GGT), BMI, and waist circumference, the HSI has shown comparable or slightly lower AUROC values but has the advantage of requiring fewer laboratory tests. A recent multicenter study found that the HSI demonstrated superior diagnostic performance (AUC 0.80) compared to visceral fat measurement (0.70), HOMA-IR (0.70), and waist-to-hip ratio (0.66) in subjects with MAFLD/MASLD.

Comparison with Other Non-Invasive Steatosis Screening Tools

Several non-invasive screening tools have been developed to identify hepatic steatosis, each with distinct advantages and data requirements. The Fatty Liver Index (FLI) uses BMI, waist circumference, triglycerides, and GGT, providing scores from 0 to 100 with a cutoff of 60 for detecting steatosis. The FLI has a well-validated AUROC of approximately 0.84 but requires waist circumference measurement and additional laboratory values not always available from routine blood work.

The SteatoTest combines ALT, alpha-2-macroglobulin, apolipoprotein A1, haptoglobin, total bilirubin, GGT, total cholesterol, triglycerides, glucose, and BMI adjusted for age and sex. While highly accurate, it requires specialized laboratory tests not routinely ordered in many clinical settings. The NAFLD Liver Fat Score uses metabolic syndrome status, type 2 diabetes, fasting insulin, fasting AST, and the AST/ALT ratio. The US Fatty Liver Index (USFLI) was developed specifically for the US population using data from NHANES.

The HSI stands out among these tools for its simplicity. It requires only ALT, AST, weight, height, sex, and diabetes status, all of which are typically available from routine clinical encounters. This makes the HSI particularly well-suited for large-scale epidemiological screening, primary care assessment, and resource-limited settings where advanced laboratory tests or imaging are not readily available.

Role of ALT and AST in Liver Health Assessment

Alanine aminotransferase (ALT), also known as serum glutamic-pyruvic transaminase (SGPT), is the most liver-specific aminotransferase enzyme. It is found primarily in hepatocytes, with much lower concentrations in cardiac, renal, and muscle tissue. ALT plays a crucial metabolic role by facilitating the formation of glutamate and pyruvate, which are important for energy production in the liver. Normal ALT reference ranges vary between laboratories but are typically reported as 7 to 56 U/L. However, research suggests that truly healthy upper limits may be lower: approximately 29 to 33 U/L for males and 19 to 25 U/L for females.

Aspartate aminotransferase (AST), also known as serum glutamic-oxaloacetic transaminase (SGOT), is present in the liver but also in the heart, skeletal muscle, kidneys, brain, and red blood cells. Normal AST reference ranges are typically 10 to 40 U/L. Because AST is present in multiple organ systems, elevated AST alone is less specific for liver disease than ALT elevation. However, the ratio of ALT to AST provides valuable diagnostic information. In simple hepatic steatosis and NAFLD, ALT typically exceeds AST. As liver disease progresses to cirrhosis, the ratio reverses, with AST exceeding ALT.

It is important to note that factors outside liver disease can affect ALT and AST levels. Intense physical exercise, particularly resistance training, can transiently elevate both enzymes. AST levels may rise to 100 to 1,000 U/L following intense exercise, with ALT rising to 50 to 200 U/L. Certain medications, including statins, NSAIDs, and antibiotics, can also affect liver enzyme levels. Patients should ideally avoid intense exercise for 2 to 3 days before blood testing and inform their healthcare provider about all medications and supplements.

BMI: Calculation, Interpretation, and Limitations in the HSI

Body mass index serves as a straightforward anthropometric measure of body composition, calculated by dividing weight in kilograms by the square of height in meters. The World Health Organization classifies BMI as follows: underweight (below 18.5), normal weight (18.5 to 24.9), overweight (25.0 to 29.9), obese class I (30.0 to 34.9), obese class II (35.0 to 39.9), and obese class III (40.0 and above). In Asian populations, lower BMI cutoffs are often used: overweight begins at 23.0 and obesity at 25.0 to 27.5, reflecting the higher metabolic risk at lower BMI values in these populations.

BMI directly contributes to the HSI score as a continuous variable, reflecting the strong dose-response relationship between adiposity and hepatic fat accumulation. However, BMI has well-known limitations as a measure of adiposity. It does not distinguish between lean mass and fat mass, nor does it account for fat distribution. Individuals with high muscle mass may have elevated BMI without excess body fat, while individuals with normal BMI but high visceral fat (sometimes called “lean NAFLD” or “lean MASLD”) may have significant hepatic steatosis. Studies have shown that lean NAFLD affects up to 40% of chronic liver disease patients in some populations, with prominent insulin resistance despite lower BMI.

Despite these limitations, BMI remains a practical and universally available measurement that significantly contributes to the predictive accuracy of the HSI. The combination of BMI with liver enzyme ratios and metabolic risk factors (diabetes, sex) helps compensate for BMI’s individual limitations.

Diabetes Mellitus and Hepatic Steatosis

Type 2 diabetes mellitus and MASLD share a bidirectional relationship driven by insulin resistance, a common pathophysiologic mechanism. The global pooled prevalence of NAFLD/MASLD among patients with type 2 diabetes is approximately 65%, with rates as high as 69% in recent studies from 2016 to 2021. Among patients with both diabetes and NAFLD/MASLD, approximately two-thirds have NASH/MASH, and approximately 15% have advanced fibrosis.

The HSI assigns an additional 2 points for the presence of diabetes mellitus, recognizing this strong association. Insulin resistance promotes hepatic lipogenesis (fat production in the liver), impairs hepatic fatty acid oxidation, and increases the flux of free fatty acids from adipose tissue to the liver. These metabolic derangements create a vicious cycle where hepatic steatosis further worsens insulin resistance, promoting progression from simple steatosis to NASH/MASH and potentially to fibrosis and cirrhosis.

For individuals with diabetes, the presence of hepatic steatosis carries additional prognostic significance. Multiple studies have demonstrated that MASLD in diabetic patients is associated with higher rates of cardiovascular disease, chronic kidney disease, and all-cause mortality compared to diabetic patients without fatty liver. This makes screening with tools like the HSI particularly important in diabetic populations.

Sex Differences in Fatty Liver Disease

The HSI includes a sex modifier that adds 2 points for female patients. This adjustment accounts for several biological differences in liver metabolism, enzyme distribution, and metabolic risk between sexes. Men generally have higher ALT levels than women at baseline, partly due to differences in muscle mass, hormonal influences, and hepatic enzyme expression. Without the sex adjustment, the HSI might underestimate fatty liver risk in women relative to men.

Epidemiological data show that the global prevalence of NAFLD is higher in men (approximately 37%) compared to women (approximately 26%), though this gap narrows significantly after menopause. Estrogen appears to have a protective effect against hepatic fat accumulation, and the decline in estrogen levels during menopause is associated with increased risk of MASLD and metabolic syndrome. Premenopausal women tend to store fat subcutaneously rather than viscerally, which is associated with lower metabolic risk, while postmenopausal women shift toward a more central fat distribution pattern similar to men.

The sex modifier in the HSI also indirectly accounts for the lower normal ALT thresholds in women. Since women typically have lower baseline ALT levels, the same absolute ALT value may represent a greater relative elevation in a female patient compared to a male patient. The additional 2 points help calibrate the index to account for these sex-based physiological differences.

Global Application and Population Considerations

While the HSI was developed in a predominantly Korean population, it has been studied and applied in diverse populations worldwide across North America, Europe, Asia, the Middle East, Africa, and other regions. Validation studies have generally confirmed its utility, though diagnostic performance may vary somewhat across different ethnic groups and clinical settings.

Some studies suggest the HSI may overestimate risk in certain populations and underestimate it in others, largely due to differences in body composition, metabolic profiles, and genetic susceptibility to fatty liver disease. For example, South Asian populations have been shown to develop metabolic complications at lower BMI thresholds, while some East Asian populations may have different ALT/AST distribution patterns. Healthcare providers globally may consider using population-specific cutoff values when available or combining the HSI with additional clinical information for optimal screening accuracy.

Alternative regional calculators exist that may complement the HSI in specific clinical contexts. The QRISK calculator (developed for use primarily in the United Kingdom) focuses on cardiovascular risk but shares overlapping risk factors with MASLD. The European SCORE system evaluates cardiovascular risk in European populations. The Fatty Liver Index was developed in an Italian population and has been extensively validated in European cohorts. Using multiple complementary tools can improve overall screening accuracy, particularly in populations where the HSI has not been extensively validated.

Limitations of the Hepatic Steatosis Index

While the HSI is a valuable screening tool, it has several important limitations that clinicians and patients should understand. First, the HSI was designed to detect hepatic steatosis (fatty liver) but does not assess the degree of liver inflammation, fibrosis, or disease severity. A high HSI score indicates the likely presence of fat in the liver but cannot distinguish between simple steatosis and more advanced NASH/MASH with fibrosis. Patients with high HSI values should undergo further evaluation to determine disease severity.

Second, the HSI can be affected by conditions other than fatty liver disease. Elevated ALT levels from other causes, including viral hepatitis, autoimmune hepatitis, drug-induced liver injury, celiac disease, or intense physical exercise, can produce falsely elevated HSI values. Similarly, conditions that affect AST levels, including muscle disease, cardiac disease, or hemolytic disorders, can alter the ALT/AST ratio and affect HSI accuracy. The HSI was developed specifically in populations with non-alcoholic fatty liver disease, and its validity in individuals with significant alcohol consumption has not been established.

Third, the binary diabetes variable (present or absent) does not capture the full spectrum of insulin resistance, which ranges from normal insulin sensitivity through prediabetes to established diabetes. Individuals with prediabetes or insulin resistance without a formal diabetes diagnosis may have their risk underestimated by the HSI. Fourth, the use of BMI rather than more precise measures of adiposity (such as waist circumference, visceral fat area, or body fat percentage) means that individuals with lean NAFLD or high muscle mass may be misclassified.

Finally, the indeterminate zone between HSI values of 30 and 36 leaves a substantial proportion of screened individuals without a clear classification, necessitating additional clinical evaluation. Despite these limitations, the HSI remains one of the simplest and most practical screening tools available for hepatic steatosis in clinical practice.

When to Seek Professional Medical Advice

The Hepatic Steatosis Index is a screening tool, not a diagnostic instrument. Several situations warrant prompt consultation with a healthcare professional. If your HSI score is 36 or above, you should discuss your results with a physician, who may recommend liver ultrasonography, additional blood tests (including a complete liver panel, lipid profile, fasting glucose or HbA1c), and assessment of other metabolic risk factors.

If you have an HSI in the indeterminate range (30 to 36) along with any metabolic risk factors such as obesity, diabetes, high blood pressure, elevated cholesterol or triglycerides, or a family history of liver disease, further evaluation is advisable. If you have been diagnosed with type 2 diabetes, regular screening for fatty liver disease should be part of your comprehensive diabetes management plan, as guidelines from the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), the American Diabetes Association (ADA), and the American Gastroenterological Association (AGA) all recommend risk stratification for MASLD in diabetic patients.

Importantly, even individuals with a low HSI score should not ignore persistent symptoms such as unexplained fatigue, right upper abdominal discomfort, unexplained weight gain, or abnormal liver function tests. No screening tool is 100% sensitive, and clinical symptoms should always be evaluated by a qualified healthcare professional regardless of screening results.

Lifestyle Modifications for Fatty Liver Disease

For individuals identified as having or being at risk for hepatic steatosis, evidence-based lifestyle modifications represent the cornerstone of management. Weight loss of 5% to 10% of body weight has been shown to significantly reduce hepatic fat content, improve liver enzyme levels, and even reverse histological features of NASH/MASH. A reduction of 7% or more in body weight is particularly associated with improvement in liver inflammation, while a 10% or greater reduction has been associated with fibrosis regression.

Dietary modifications should emphasize whole, unprocessed foods while reducing intake of added sugars, refined carbohydrates, and saturated fats. The Mediterranean diet has the strongest evidence base for improving fatty liver disease, with multiple randomized controlled trials demonstrating reductions in hepatic fat content, improved insulin sensitivity, and reduced cardiovascular risk. Key components include abundant fruits and vegetables, whole grains, legumes, nuts, olive oil as the primary fat source, moderate fish consumption, and limited red meat.

Regular physical activity is recommended regardless of weight loss. Both aerobic exercise (such as brisk walking, cycling, or swimming for 150 to 300 minutes per week) and resistance training (2 or more sessions per week) have been shown to reduce hepatic fat independently of weight loss. Reducing sedentary behavior and limiting alcohol consumption (even in individuals whose fatty liver is not alcohol-related) are additional important lifestyle measures. Individuals with diabetes should optimize glycemic control, as improved blood sugar management is associated with reduced hepatic steatosis.

Emerging Pharmacological Therapies for MASLD/MASH

While lifestyle modification remains the primary treatment for MASLD, the therapeutic landscape is rapidly evolving with several pharmacological agents showing promise. In 2024, resmetirom (Rezdiffra) became the first FDA-approved therapy specifically for MASH with moderate to advanced liver fibrosis, representing a landmark development in the field. Resmetirom is a liver-directed thyroid hormone receptor-beta agonist that reduces liver fat and has demonstrated fibrosis improvement in clinical trials.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide, primarily developed for type 2 diabetes and obesity management, have shown significant benefits for MASLD, including reduction in hepatic fat, improvement in NASH histology, and weight loss. Dual and triple incretin agonists (such as tirzepatide, a GIP/GLP-1 receptor agonist) are also showing promising results for liver fat reduction. Other therapeutic approaches under investigation include FXR agonists, PPAR agonists, ACC inhibitors, and various anti-fibrotic agents.

Screening tools like the HSI play an important role in the evolving treatment landscape by identifying individuals who may benefit from further evaluation and potentially from these emerging therapies. Early identification of hepatic steatosis allows for timely intervention before disease progression to more advanced stages where therapeutic options may be more limited.

How to Use the HSI Calculator

Using the Hepatic Steatosis Index calculator involves entering a few simple values from your recent blood test results and basic measurements. First, enter your ALT (alanine aminotransferase) level in U/L as reported on your blood test. ALT may also be listed as SGPT on some laboratory reports. Second, enter your AST (aspartate aminotransferase) level in U/L, which may also be listed as SGOT. Third, enter your weight and height to calculate your BMI, or enter your BMI directly if you already know it. Fourth, indicate whether you have been diagnosed with type 2 diabetes mellitus. Fifth, select your biological sex.

The calculator will automatically compute your HSI score and provide an interpretation based on the validated clinical thresholds. Values below 30 suggest NAFLD is unlikely, values between 30 and 36 are indeterminate, and values of 36 or above suggest NAFLD is likely present. The calculator also displays your computed BMI, ALT/AST ratio, and a visual representation of where your score falls on the risk spectrum.

For the most accurate results, use liver enzyme values from a fasting blood test obtained when you are not acutely ill, have not engaged in intense physical exercise within the preceding 2 to 3 days, and are not taking medications known to significantly affect liver enzyme levels. If your enzyme levels seem unexpectedly high or low, consider repeating the test after addressing potential confounding factors. Remember that different laboratories may use slightly different reference ranges and measurement methods.

Understanding Your Blood Test Results for the HSI

Laboratory blood tests report ALT and AST values in units per liter (U/L) or international units per liter (IU/L), which are equivalent measures. When reading your blood test results, look for ALT (or SGPT) and AST (or SGOT) in the liver function test section, sometimes called a hepatic panel, liver panel, or comprehensive metabolic panel. The normal reference ranges provided on your laboratory report are specific to that laboratory’s methods and reference population.

Typical reference ranges for ALT are 7 to 56 U/L, and for AST are 10 to 40 U/L, though these can vary between laboratories. Some experts advocate for lower upper limits of normal (30 U/L for males and 19 U/L for females for ALT) to improve sensitivity for detecting early liver disease. For the purposes of the HSI calculation, use the actual numerical values from your blood test, regardless of whether the lab flags them as normal or abnormal.

If your blood test was conducted in different units (such as microkatal per liter), a conversion may be necessary. The conversion factor is approximately: 1 U/L equals 0.0167 microkatals per liter (ukat/L). However, most clinical laboratories worldwide report aminotransferase values in U/L or IU/L. If you are unsure about your laboratory values, consult with your healthcare provider for clarification.

Regional Variations and Alternative Calculators

The landscape of non-invasive screening tools for hepatic steatosis continues to expand, with different tools offering advantages in specific populations or clinical contexts. The Fatty Liver Index (FLI), developed in an Italian population, has been extensively validated in European cohorts and is widely used in epidemiological research. It uses BMI, waist circumference, triglycerides, and GGT, with scores from 0 to 100 and a cutoff of 60 for predicting steatosis.

The NAFLD Fibrosis Score (NFS) and Fibrosis-4 (FIB-4) Index, while focused on fibrosis rather than steatosis, are important complementary tools that can help stratify risk beyond fat accumulation. The NFS uses age, BMI, presence of impaired fasting glucose or diabetes, AST/ALT ratio, platelet count, and albumin. The FIB-4 Index uses age, AST, ALT, and platelet count. Healthcare providers may use these fibrosis-oriented tools alongside the HSI for a more comprehensive non-invasive assessment.

Imaging-based methods remain the reference standards for non-invasive steatosis assessment. Liver ultrasonography is widely available, inexpensive, and can detect moderate to severe steatosis but has limited sensitivity for mild steatosis (hepatic fat content below 20 to 30%). Controlled attenuation parameter (CAP) using transient elastography (FibroScan) provides quantitative steatosis assessment with better sensitivity but requires specialized equipment. MRI-PDFF is considered the most accurate non-invasive method for quantifying liver fat but is expensive and not widely available for routine screening.

The NAFLD to MASLD Nomenclature Transition

In 2023, a multi-society Delphi consensus process led by hepatology organizations worldwide resulted in a significant nomenclature change, replacing non-alcoholic fatty liver disease (NAFLD) with metabolic dysfunction-associated steatotic liver disease (MASLD). This change was driven by several considerations. The term “non-alcoholic” was considered stigmatizing and defined the condition by what it was not, rather than by its underlying pathophysiology. The new name highlights the metabolic underpinnings of the disease, including insulin resistance, dyslipidemia, obesity, and other metabolic risk factors.

Under the new classification, MASLD requires at least one cardiometabolic risk factor in addition to hepatic steatosis. NASH has been renamed to metabolic dysfunction-associated steatohepatitis (MASH). The umbrella term steatotic liver disease (SLD) now encompasses MASLD, alcohol-related liver disease (ALD), MetALD (for individuals with both metabolic and alcohol-related contributions), and other specific etiologies. Most individuals previously classified as having NAFLD meet the criteria for MASLD.

The HSI was developed under the NAFLD nomenclature, and its validation studies predominantly use this terminology. However, given that the vast majority of NAFLD patients meet MASLD criteria, the clinical utility of the HSI applies equally under the new nomenclature. Healthcare providers and researchers are gradually transitioning to the MASLD terminology, and both terms may be encountered in clinical practice during this transition period.

Frequently Asked Questions

Conclusion

The Hepatic Steatosis Index represents a practical, evidence-based screening tool for identifying individuals at risk of fatty liver disease using readily available clinical data. With MASLD affecting nearly one-third of the global adult population and its prevalence projected to continue rising, accessible screening tools are essential for early detection and intervention. The HSI’s simplicity, requiring only ALT, AST, BMI, diabetes status, and sex, makes it uniquely suited for widespread use in diverse healthcare settings, from primary care clinics to large-scale epidemiological studies.

While the HSI has demonstrated good diagnostic accuracy with an AUROC of 0.812 and validated thresholds that provide high sensitivity for ruling out disease and high specificity for detecting it, it should be considered a screening tool rather than a definitive diagnostic test. A positive HSI result should prompt further evaluation with imaging and additional clinical assessment, while a negative result provides reassurance that can be supplemented with clinical judgment. As our understanding of MASLD continues to evolve and new therapeutic options become available, tools like the HSI will play an increasingly important role in identifying individuals who can benefit from early intervention and ongoing monitoring.

We encourage all individuals with metabolic risk factors to discuss liver health screening with their healthcare provider. Early detection of hepatic steatosis provides an opportunity for evidence-based lifestyle modifications and, when indicated, pharmacological interventions that can prevent disease progression and improve long-term health outcomes. This calculator is intended as an educational and screening aid and should always be used in conjunction with professional medical guidance.